Skip to main navigation
logo
SAB Biotherapeutics Logo
  • OVERVIEW
    Corporate Video Executive Management Board of Directors Board Committees Corporate Governance Scientific Advisory Board
  • Platform
    Scientific Platform Publications
  • Pipeline
    Pipeline Overview SAB-195: CDI SAB 176: Influenza
  • PARTNERING
  • Patients
    C. diff Patient Information Influenza
  • Media
    News & Press Releases Events Presentations Publications
  • Shareholder Services
    Overview SEC Filings Stock Quote & Chart Corporate Governance Board Committees Analyst Coverage RSS Feeds Contact Us

News Releases

Jan 19, 2023
SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
Conference to take place Feb. 6-9 in New York SIOUX FALLS, S.D., Jan. 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human
Jan 18, 2023
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
SIOUX FALLS, S.D., Jan. 18, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human
Jan 10, 2023
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
Study shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is well tolerated; next step is investigational new drug (IND) filing SIOUX FALLS, S.D., Jan. 10, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a
Jan 09, 2023
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
SIOUX FALLS, S.D., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human
Jan 05, 2023
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
SIOUX FALLS, S.D., Jan. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, announced

Shareholder Tools

  • Print Page
  • Email Alerts
  • RSS
  • Investor FAQs
  • © SAB Biotherapeutics 2023

Footer Links

  • Terms & Conditions
  • Privacy Policy